MacroGenics (MGNX) Expected to Post Quarterly Earnings on Wednesday

MacroGenics (NASDAQ:MGNX) will likely be issuing its Q3 2026 results after the market closes on Wednesday, November 11th. Analysts expect MacroGenics to announce earnings of ($0.3151) per share and revenue of $39.18 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

MacroGenics (NASDAQ:MGNX) last announced its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.39. The firm had revenue of $32.83 million during the quarter, compared to the consensus estimate of $59.14 million. MacroGenics had a negative net margin of 8.70% and a negative return on equity of 109.26%. On average, analysts expect MacroGenics to post ($1.14) EPS for the current fiscal year and ($1.25) EPS for the next fiscal year.

MacroGenics Stock Up 2.6%

NASDAQ:MGNX traded up $0.06 on Wednesday, reaching $2.39. The stock had a trading volume of 25,446 shares, compared to its average volume of 956,373. The company has a market capitalization of $152.24 million, a P/E ratio of -10.85 and a beta of 1.33. MacroGenics has a 1-year low of $1.29 and a 1-year high of $5.08. The stock has a fifty day moving average price of $3.62 and a 200-day moving average price of $3.41.

Insider Activity

In other news, VP Jeffrey Peters sold 31,105 shares of the stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $4.15, for a total transaction of $129,085.75. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 13.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on MGNX. Weiss Ratings reiterated a “sell (d-)” rating on shares of MacroGenics in a research note on Tuesday. B. Riley Financial boosted their target price on MacroGenics from $9.00 to $11.00 and gave the stock a “buy” rating in a report on Monday, August 17th. Finally, Citigroup began coverage on MacroGenics in a research report on Friday, October 23rd. They set a “positive” rating on the stock. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, MacroGenics presently has a consensus rating of “Hold” and a consensus target price of $8.50.

MacroGenics Company Profile

MacroGenics, Inc is a biopharmaceutical company focused on developing antibody-based therapies for cancer and immune-mediated diseases. Headquartered in Rockville, Maryland, the company uses its proprietary DART platform and other antibody technologies to create treatments designed to modulate immune responses and target disease-associated cells.

MacroGenics’ portfolio includes MARGENZA (margetuximab-cmkb), an antibody therapy approved in the United States for certain patients with HER2-positive metastatic breast cancer.